NIH Rejects Compulsory License For Abbott's Norvir

Law360, New York (August 5, 2004, 12:00 AM EDT) -- A U.S. government agency has rejected calls for a compulsory license for a popular HIV medicine used to boost AIDS drugs, dealing a setback for activists who had hoped to use a little-known law to override a drug maker’s patent rights.

In its ruling, the National Institutes of Health rejected a "march-in petition" filed by Essential Inventions, which urged the NIH to claim control over patent rights to Norvir, a drug sold by Abbott Laboratories. The group asked the NIH to act after Abbott raised the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.